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Background. Evidence is emerging that molecular chaperones, in addition to their intracellular protein folding actions, can act
as intercellular signaling proteins with an ability to modulate leukocyte function. Recent evidence has also shown that these
proteins can exist in the circulation and may be involved in disease pathogenesis. We have used periodontitis and its
treatment as a model of inflammation in the human to determine its effects on levels of circulating HSP10, HSP60 and BiP.
Methodology/Principal Findings. A group of periodontal patients and matched controls were examined at the beginning of
the study and then at 1 day and 6 months following periodontal or control therapy. Plasma levels of HSP10, HSP60 and BiP
were measured by immunoassay and related to other plasma measures of inflammation. Periodontal patients had significantly
less circulating levels of HSP10 or BiP compared with the controls. In contrast, more periodontal patients had intermediate
levels of HSP60. Treatment of the periodontitis caused an increase in plasma levels of HSP10 although it had no effect on BiP.
Treatment had no influence of HSP60 levels. Plasma HSP10 levels after therapy correlated with markers of periodontal clinical
improvement. Conclusions/Significance. Circulating levels of molecular chaperones are influenced by local inflammation.
HSP10 is known to be an anti-inflammatory factor. The marked decrease of this circulating protein in active inflammation and
its recovery post-treatment suggests that it may have a role in controlling periodontal inflammation.
Citation: Shamaei-Tousi A, D’Aiuto F, Nibali L, Steptoe A, Coates ARM, et al (2007) Differential Regulation of Circulating Levels of Molecular
Chaperones in Patients Undergoing Treatment for Periodontal Disease. PLoS ONE 2(11): e1198. doi:10.1371/journal.pone.0001198
INTRODUCTION
A major breakthrough in our understanding of cell biology was the
discovery of the cell stress response and the role played in this
response by inducible molecular chaperones [1,2]. Molecular
chaperones are proteins best known for their ability to fold
unfolded proteins. However, two other, potentially related,
biological functions of molecular chaperones were discovered
contemporaneously with their folding actions. Many of the
molecular chaperones of bacteria and parasites are potent
immunogens [3,4]. This has always been a paradoxical finding
given the substantial sequence conservation between these proteins
[4]. Although first discovered in the 1980s, it is only in the past
decade that attention has focused on the finding that many
molecular chaperones, particularly from eukaryotes, have in-
tercellular signalling activity [5]. This may have remained just an
interesting laboratory artefact but for the finding that a growing
number of molecular chaperones exist in the human circulation.
The first molecular chaperone (although it was not known that this
was its function at the time) to be identified in human blood was
heat shock protein (Hsp)10. This was identified as an immuno-
suppressive factor in the blood of pregnant women in the first
trimester and was named early pregnancy factor (EPF) [6]. This
was later identified as HSP10 [7]. Most attention has focused on
circulating levels of the co-chaperone of HSP10, a protein termed
HSP60. Circulating levels of HSP60 have been correlated with
susceptibility to cardiovascular disease [8–13]. Members of the
Hsp70 family such as Hsp70 [14,15] and BiP [16] have been
found in blood, and with the former, levels in the blood inversely
correlate with cardiovascular disease severity [15].
Initial studies of the cell signalling actions of molecular chaperones
suggested that they acted as pro-inflammatory mediators with actions
similar to interleukin-1 or tumour necrosis factor alpha [5]. However,
it has recently become apparent that certain molecular chaperones
such as HSP10 [17] and BiP [18] act to inhibit the pro-inflammatory
actions of myeloid cells. Indeed, HSP10 has recently been shown to
inhibit joint inflammation in patients with rheumatoid arthritis [19].
Periodontal disease is a very common chronic inflammatory
condition which can be simplistically viewed as a disease caused by
the overgrowth of the normal oral bacterial microflora (dental
plaque) associated with an exaggerated local host inflammatory
response [20]. Treatment of this condition consists of mechanical
removal of dental plaque and leads to rapid changes in
inflammation locally, but can provide a systemic inflammatory
insult due to the release of bacteria and their phlogistic products
into the blood [21]. Our aim was therefore to utilize periodontitis
and its treatment as a human model to determine how levels of
circulating molecular chaperones relate to the presence and
changes in local and systemic inflammation [22].
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RESULTS
Case-Control Study
The serum baseline characteristics of periodontal patients and
controls are reported in Table 1. Age, gender, ethnicity and
smoking habits were similar between groups. As expected from
previous studies [21], the patients with periodontitis exhibited
higher levels of CRP (median difference 0.6 mg/ml, 95%CI 0.1–
1.2, P,0.05), IL-6 (median difference 0.6 pg/ml, 95%CI 0.3–1.0,
P,0.01) and total leukocyte counts (mean difference 0.8 109cells/
L, 95%CI 0.2–1.4, P,0.01) when compared to controls. There
was also an association between periodontitis and lower HDL
levels (mean difference between groups 0.1 mmol/L, 95%CI 0–
0.3, P,0.05) and higher glucose concentrations (mean difference
between groups 0.3 mmol/L, 95%CI 0.1–0.6, P,0.05).
Subjects with periodontitis had markedly lower plasma
concentrations of HSP10 (median difference 404.8 mg/ml, 95%
CI 332.4–499.1, P,0.0001) and lower concentrations of BiP
(median difference 417.9 mg/ml, 95% CI 336.8–503.3, P,0.05)
when compared to controls. After adjustment for age, gender,
ethnicity and cigarette smoking, the odds for high HSP10
($1000 ng/ml) were 15.6 (95% CI 5.9–41.3) for controls
compared to subjects with periodontitis. In contrast, there was
a weaker association between periodontitis and HSP60 levels
(Figure 1).
However, HSP60 levels were stratified into those with:
undetectable, between 1 and 1,000 ng/ml and .1,000 ng/ml
HSP60 and we found a significant difference between controls and
patients in the numbers of individuals having medium (between 1
and 1,000ng/ml) levels of circulating HSP60. Thus many more
periodontal patients had medium levels of circulating HSP60 and
the odds for medium HSP60 were 3.4 (95% CI 1.2–10) higher for
patients with periodontitis compared to controls (Figure 2).
We also observed a consistent inverse association between
plasma concentrations of HSP10and clinical periodontal param-
eters (averaged whole mouth probing depths, r = 0.31, P = 0.022;
averaged whole mouth number of periodontal lesions r = 0.32,
P= 0.032 and whole mouth supra-gingival plaque scores, r = 0.33,
P= 0.002).
Intervention Study
After 6 months of therapy, subjects in the IPT group presented
with lower gingival plaque scores (mean between groups difference
29%, 95% 21–37, P,0.0001) and lower numbers of periodontal
pockets (mean between group difference 62, 95% 53–71,
P,0.0001) when compared to controls. Of the circulating
molecular chaperones being measured, we only observed an
association between periodontal therapy and the concentrations of
plasma HSP10 (Figure 3). Within 24hrs of therapy the IPT
patients exhibited substantial increases in their plasma concentra-
tions of HSP10 (difference between changes from baseline between
groups 1633 ng/ml , 95%CI 181–3086, P= 0.21) but with great
variability among individuals. This increase in circulating HSP10
was still measurable 6 months after therapy (difference between
changes from baseline between groups 1105, 95%CI 89–2575,
P= 0.034) (Figure 3). The covariance analysis revealed that these
changes were independent of age, gender, ethnicity and smoking
differences between study treatment groups. There was also a dose-
response positive association between improvements in clinical
periodontal parameters (reduction in number of periodontal
pockets lesions between baseline and 6 months) and increases in
HSP10 plasma concentrations (r = 0.29, P = 0.028). No other
differences were observed in all the other biological markers
between study groups after 6 months of therapy including the
significant difference in the proportion of patients with HSP60
levels between 1 and 1,000 ng/ml.
DISCUSSION
The inflammatory response is a complex system involving the
interactions of leukocytes with activated vascular endothelial cells.
This system has to be tightly controlled, and the discovery of
cytokines, beginning in the 1970s, provided what appeared to be
the major class of inflammatory control protein [23]. Inflamma-
Table 1. Case control study
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Control Group (N=48) Periodontitis Group (N= 80) P value*
Age, years 43 (40–47) 44 (43–45) 0.623
Male Gender, no. (%) 22 (46) 42 (50) 0.718
Smokers, no. Current (%) 10 (21) 25 (30) 0.309
Race or ethnic group, no. Caucasians(%) 39 (81) 57 (68) 0.108
CRP, mg/L 2.18 (1.07–3.28) 2.86 (2.10–3.62) 0.026
IL-6, pg/ml 2.17 (1.57–2.77) 2.34 (0.71–3.98) 0.005
Leucocytes count, 109 cells/L 5.91 (5.50–6.32) 6.67 (6.11–7.23) 0.042
Cholesterol, mmol/L 5.34 (4.97–5.71) 4.82 (4.55–5.08) 0.148
HDL-Cholesterol, mmol/L 1.65 (1.52–1.77) 1.47 (1.36–1.59) 0.041
LDL-Cholesterol, mmol/L 3.02 (2.70–3.33) 2.76 (2.52–3.00) 0.264
Glucose, mmol/L 4.76 (4.55–4.97) 4.96 (4.81–5.11) 0.019
Triglycerides, mmol/L 1.42 (1.10–1.74) 1.26 (0.95–1.57) 0.182
HSP10, mg/ml; median(IQR) 549.50 (579.1) 0.10 (543.2) ,0.0001
BiP, mg/ml; median(IQR) 743.45 (1940.7) 478.75 (1225.8) 0.031
HSP-60, mg/ml; median(IQR)** 0.83 (1734.4) 32.50 (573.9) 0.478
*Differences were computed with parametric (Independent t-test) or non parametric (Mann-Whitney U-Test) dependent upon the data frequency distribution.
Categorical variables were analyzed by Chi-square testing.
**See Figure 2.
doi:10.1371/journal.pone.0001198.t001..
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tion is stressful, and it is perhaps not surprising that it is associated
with alterations in heat shock/cell stress protein expression
[24,25]. Two unexpected discoveries, which are still the cause of
some controversy, are that: (i) many molecular chaperones have
intercellular signaling actions particularly with myeloid, lymphoid
and vascular endothelial cells [26] and (ii) molecular chaperones
can be found in the blood [27]. Initial studies suggested that
molecular chaperones were pro-inflammatory factors able to
activate myeloid and vascular endothelial cells [28]. However,
subsequent work has revealed that molecular chaperones such as
BiP [18] and HSP10 [17] are able to inhibit myeloid cell
activation. It has also been shown that human HSP60, while able
to activate human myeloid cells [reviewed in 28] has the ability to
inhibit lymphocyte activation [29]. The first molecular chaperone
to be identified in blood from normal individuals was HSP60 [30].
Since then levels of this molecular chaperone have been shown to
correlate with measures of cardiovascular pathology in a number
of studies [27]. However, almost nothing is known about
circulating levels of other molecular chaperones such as BiP or
HSP10 in human blood or how such levels relate to disease status.
Periodontal disease is a very common condition in which
inflammation of the gingivae is associated with destruction of the
periodontal ligament and alveolar bone which support the
dentition. This disease is a response to overgrowth and down-
growth of suspected periodontal bacterial pathogens. Non-surgical
and surgical periodontal therapy results in removal of these
bacteria which can rapidly decrease the local inflammation in the
gingivae while causing a short-term systemic inflammatory
response as a result of local tissue damage and the release of
bacterial phlogistic mediators such as Gram-negative lipopolysac-
charide [21]. This ability to be able to modulate the human
inflammatory response makes periodontal disease a potential
model system for studying the control of inflammation directly in
the human subject.
In the present study we have assayed the concentrations of three
molecular chaperones, HSP10, HSP60 and BiP in the blood of
Figure 1. Differences in plasma concentrations between patients
suffering from periodontitis (N=80) and age-matched unaffected
controls (N=48). Boxes refer to the 25th (bottom) and 75th (up)
percentiles and the median is the large horizontal line, fences refer to
the 10th (lower) and 90th (upper) percentiles respectively. Open circles
represent outliers whereas asterisks stand for extreme observations with
the subject number. Statistical differences are computed with Mann-
Whitney U-test.
doi:10.1371/journal.pone.0001198.g001
Figure 2. Number of individuals among test (periodontitis) and
control (healthy) groups according to HSP60 levels being undetect-
able, less or greater than 1000 ng/ml. Asterisk refers to statistically
significant differences (P,0.05) between groups within each category
as computed with Chi-square test.
doi:10.1371/journal.pone.0001198.g002
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Figure 3. Mean values (standard errors) and mean changes (standard errors) (compared to baseline) of HSP10 (A–B), BiP (C–D) and HSP60 (E–F)
before, 24 hrs after and 6 months after periodontal therapy. Positive differences indicate a relative increase in plasma concentrations of various
markers compared to the pre-treatment baseline. Subjects who received intensive periodontal therapy (open circles, N = 40) showed greater plasma
concentrations of HSP10 at each time visit when compared to control therapy group subjects (filled circles, N = 40). No other changes were observed.
Asterisks refer to statistically significant difference (P,0.05) between groups as computed with analysis of covariance.
doi:10.1371/journal.pone.0001198.g003
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patients with periodontal disease and compared this with a group
of age-, gender- and ethnically-matched non-diseased controls.
This revealed that there was no difference in the overall
concentrations of HSP60 in both groups. However, HSP60 levels
in blood are stratified with around 50% having no measurable
protein, 25% having high levels (.1 mg/ml) and the remainder with
levels in the range 1–1,000 ng/ml. Comparison of these three
distinct concentration bands revealed a significantly higher number
of periodontal patients with intermediate levels of HSP60 compared
to controls. Evidence from the literature tends to suggest that high
levels of HSP60 are pro-inflammatory but lower levels are anti-
inflammatory [29]. It is interesting to speculate whether individuals
with low levels of HSP60 have their local anti-bacterial defences
compromised by the action of this protein?
Levels of the endoplasmic reticulum cell stress protein BiP were
significantly lower in the plasma of the periodontal patients than in
controls. This protein is an active anti-inflammatory molecule
both in vitro and in vivo, and so lower levels in individuals with on-
going inflammation are a consistent finding.
The results for HSP10 levels were even more striking with the
concentrations of this stress protein in the periodontal patients
being very low compared to the matched group of controls. Of
interest was the finding in the periodontitis patients that there was
a consistent inverse association between HSP10 plasma concen-
trations and clinical parameters of periodontal disease severity,
such as the number of periodontal pockets or dental plaque scores.
The very low levels of HSP10 in the periodontal patients could
have been due to genetic or environmental factors. Fortunately,
the intervention protocol, which acted to remove the inflammatory
stimuli in these individuals, gave us a chance to test if plasma levels
of molecular chaperones were stable (genetic) or were environ-
mentally controlled.
Periodontal patients were randomly divided into two groups.
The control group received a standard cycle of supragingival
mechanical scaling and polishing. The intensive treatment group
underwent a prolonged session of full-mouth removal of
subgingival dental plaque biofilms under local analgesia as
described [31]. The latter therapy releases bacterial pro-in-
flammatory molecules into the bloodstream and causes an acute
phase response with endothelial dysfunction [31]. This is
associated with elevations of C-reactive protein and the pro-
inflammatory cytokine, interleukin (IL)-6 [31,32]. In spite of the
elevation in the levels of these pro-inflammatory indicators, the
levels of HSP10 in the circulation were increased significantly at
one day following therapy and were still elevated after 6 months,
when the acute phase protein and endothelial dysfunction had
returned to baseline, showing that levels of this protein are
environmentally controlled. In contrast, there were no significant
changes in the levels of HSP60 or BiP after therapy.
Patients with moderate to severe periodontitis reveal significant
lowering of the plasma levels of two molecular chaperones which
have anti-inflammatory actions–HSP10 and BiP when compared
with controls. Both of these proteins are able to inhibit the
activation of macrophages [17,33]. BiP has been shown to block
experimental collagen-induced arthritis in the mouse [18] and is in
early phase clinical trials for the treatment of rheumatoid arthritis.
HSP10, or early pregnancy factor (EPF) inhibits the development
of autoimmune disease in rats [34] and has recently been
administered to a small number of patients with rheumatoid
arthritis with therapeutic benefit [35]. The mechanism of action of
BiP, at least in inbred mice, is the induction of regulatory
lymphocytes that are largely controlled by IL-4 [18]. The
mechanism of immunosuppression of HSP10 is less well defined
but is believed to inhibit intracellular signaling pathways
stimulated by ligand interaction with selected Toll-like receptors
(TLRs) [17]. It is not known if this effect is mediated at the cell
surface or is an intracellular effect. There is insufficient evidence to
understand the exact role of these molecules at the gingival levels.
The decreased circulating concentrations of HSP10 in patients
with periodontitis could either be due to decreased synthesis, with
this protein therefore acting like serum albumin and transferrin as
a negative acute phase reactant, or to removal from the
circulation, as part of the anti-inflammatory activity of this
protein. Decreased synthesis of HSP10 is unlikely as the genes
encoding both HSP10 and HSP60 are organized in a head-to-
head fashion with a shared bidirectional promoter [35]. If HSP10
synthesis did decrease in periodontal disease a corresponding
decrease in HSP60 concentrations would be expected, and was not
observed in this study. Moreover, unlike conventional acute phase
proteins that are largely synthesized in the liver, HSP10 and
HSP60 are found in every cell as nuclear encoded genes which
function within the mitochondria. Thus the reduction in HSP10
levels in patients with periodontitis must be due to the removal of
this protein from the blood, potentially as part of a natural anti-
inflammatory mechanism. Treatment of the gingival/periodontal
inflammation, which results in local dampening of the inflamma-
tory mechanisms, would therefore be expected to stop the removal
of this protein from the circulation and increase levels in the blood.
What is surprising is how rapidly levels increased following an
intensive session of periodontal therapy.
In conclusion, we have discovered that periodontal disease is
associated with significant decreases in the circulating concentra-
tions of one endoplasmic reticulum molecular chaperone, BiP
which is a key controller of the unfolded protein response [36] and
a mitochondrial molecular chaperone involved in protein folding
within this organelle. Treatment of the gingival inflammation
results in a return of HSP10 levels to those found in controls but
has no effect on the lowered levels of BiP. These finding reveal that
circulating molecular chaperones are important indicators of
disease status and response to therapy and argues that we need to
understand more about the levels of these proteins in blood and
what controls their concentrations.
MATERIALS AND METHODS
Case-Control Study
Data for this experiment derives from a case-control investigation
including all individuals recruited among the population referred
for care to the Eastman Dental Hospital. Eighty subjects with
a diagnosis of moderate to severe periodontitis [37] were enrolled
at the Periodontology Unit, and 48 controls were selected among
patients attending other units (Oral Surgery or Restorative Clinics)
and presenting without clinical and radiographic signs of period-
ontitis. All individuals were: (i) free from systemic diseases as
assessed by the examining clinician; (ii) not pregnant if females
and; (iii) not on any medication. In addition, control subjects were
included only if they did not report a history of tooth loss due to
periodontitis. All subjects gave written informed consent and the
study protocol had been reviewed and approved by University
College London Hospitals and Eastman Dental Hospital joint
ethics committee.
Control subjects received a basic clinical examination (basic
periodontal screening score (BPE)), whereas a cluster of periodon-
tal parameters were collected from patients suffering from
periodontitis. These included gingival probing depth (PPD) and
recession of the gingival margin (GR) relative to the cemento-
enamel junction at 6 sites per tooth. Presence or absence of supra-
gingival dental plaque and gingival bleeding on probing were also
Hsp Levels in Periodontitis
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recorded. Averaged whole mouth number of periodontal lesions
(probing depth .4 mm), full mouth gingival bleeding scores
(relative number of sites with gingival bleeding on probing) and full
mouth plaque scores (relative number of sites with detectable
plaque) were recorded for each individual [38].
Intervention Study
For this experiment we used data from a clinical intervention trial
of patients with severe periodontitis. Inclusion criteria and clinical
parameters recorded for this population were as described above.
Eighty individuals included in the study received basic oral
hygiene instructions and then were randomized (permuted block
approach) to an intensive (IPT, N= 40) or standard cycle of
periodontal therapy (SPT, N=40). Allocation to treatment was
concealed in opaque envelopes which were opened at the time of
therapy. SPT consisted of a session of supra-gingival scaling and
polishing of the whole dentition. In contrast, the IPT group
subjects received sub-gingival mechanical instrumentation under
local anaesthesia. All patients were re-examined 24 hrs and
6 months after therapy. This is because we previously showed
that intensive periodontal therapy causes a transient systemic
inflammatory response (peak 1 day after therapy) resolving only
after 6 months [21,22]. No adverse events were reported.
Laboratory Analyses
Blood samples were collected at the baseline visit for both
investigations and also after therapy (24 hrs and 6 months) in the
intervention study. Plasma samples were immediately processed
and stored at 270uC until the analyses were performed. Routine
markers (full blood count, lipids and glucose levels) were
determined using standard biochemistry procedures. Serum
inflammatory markers were determined by high sensitivity
immunoassays (C-reactive protein: Cobas Integra 700, Roche,
Mannheim, Germany; IL-6: Quantikine HS, R&D System,
Minneapolis).
Two site ELISAs were used to measure the concentrations of
HSP10, HSP60 and BiP in plasma samples. The assay for HSP60
was as described [10,11]. To assay BiP, ELISA plates (Immuno-
sorp, Nunc) were coated with 0.125 mg mouse anti-BiP (BD
Transduction labs) in PBS overnight at 4uC. Non-specific binding
was blocked by the addition of 0.1% BSA in PBS 0.05% Tween-20
serum (Sigma) for 1 hour at room temperature. After washing,
recombinant BiP (0 to 10 000 ng/mL) or dilutions of human
plasma were added, and plates were incubated for two hours at
37uC and then washed. Samples were incubated with rabbit anti-
BiP polyclonal IgG (Santa Cruz Biotechnology; 1:400 dilution in
PBS 0.05% Tween-20 supplemented with 4% filtered normal
mouse serum) for 2 hours 37uC the wells. After washing,
biotinylated anti-rabbit IgG (Santa Cruz Biotechnology; 1:10,
000 dilution) was added and incubated at 37uC for one hour. After
a further wa step, samples were incubated with streptavidin HRP
(Sigma; 1:2 000 dilution) for 45 minutes at 37uC. Binding of
conjugated antibody was detected using TMB substrate. The
reaction was stopped with 1 mol/L H2SO4, and absorbance was
determined at 492 nm using a Dynex plate reader. Each plasma
sample was assayed in triplicate. Human plasma HSP10 was
measured using a newly developed two-site ELISA. ELISA plates
(Immunosorp, Nunc ) were coated with 10 ng of goat polyclonal
anti-HSP10 antibody (clone FL-102, corresponds to the full length
of human HSP10, Santa Cruz Biotechnology) in PBS overnight at
4uC. Plates were washed in wash buffer (0.5 mol/L NaCl,
2,5 mmol/L NaH2PO4, 7,5 mmol/L, Na2 HPO4 and 0.1%
Tween-20), and nonspecific binding sites were blocked by
incubation with 1% BSA (Sigma) in wash buffer for 4 hours at
37uC. After washing, recombinant HSP10 (Stressgen; 0 to 10,
000 ng/ml) or dilutions of human plasma were added, and plates
were incubated overnight at 4uC and then washed. Bound HSP10
was detected by incubation with goat polyclonal antibody to
HSP10 (clone C-20, Santa Cruz Biotechnology) at 1:500 for
1 hour at 37uC. After washing, plates were incubated with HRP
conjugated anti goat IgG (Sigma; 1:5000) for 1 hour at 37uC.
Binding of conjugated antibody was detected using Sigma fast
OPD (1,2-phenylenediamine dihydrochloride) substrate. The
reaction was stopped by 1 mol/L H2SO4, and absorbance was
determined at 492 nm using a Dynex plate reader. Each plasma
samples was assayed in triplicate. Plasma from individuals with the
highest plasma levels of HSP10 were assayed at least twice in
separate assays.
Statistical Analysis
As there were no previous report on the association between
periodontitis and molecular chaperones, no formal sample size
calculations were available. Data are reported as means and 95%
confidence intervals unless otherwise specified. In the case-control
experiment we compared differences in all variables between
groups by parametric (ANOVA) or non parametric (Mann-
Whitney U-test) statistics depending on the shape of the
distribution’s curve of the data. Differences between categorical
variables were computed using Chi-square testing. Logistic
regression models were used to ascertain differences between
cases and control or low versus high ($1000 ng/ml) plasma
concentrations of HSP10, HSP60 and BiP. Differences between
treatment groups for each marker in the intervention trial were
computed using analysis of covariance. Logarithmic transforma-
tion of the data was performed where appropriate. Age, gender,
ethnicity and cigarette smoking were included in each model as
covariates. Non parametric correlation analyses (Spearman rank
test) were performed to evaluate the association between bio-
markers and clinical periodontal parameters (before and after
therapy). A two-sided value of p,0.05 was considered statistically
significant using SPSS ver.13.
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